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Abstract
Purpose Only a third of children with cancer and febrile neutropenia (FN) have a proven bacterial infection; nevertheless, most
children are hospitalized and treated with intravenous antibiotics. Several biomarkers have been proposed as predictive markers
for bacterial infection in this population. We aimed to evaluate the role of interleukin-6 (IL-6) and procalcitonin (PCT) in
diagnosing bacterial infection in children with cancer and FN.
Methods The study population was derived from a prospective database (2006–2013, IL-8 study) comprising children with
cancer who presented with FN. From stored plasma samples (taken at admission and/or at 12–24 h), we determined the PCTand
IL-6 levels. Consequently, we explored their relation with the presence of bacterial infection (positive blood culture, radiolog-
ically documented infection or clinical bacterial focus). We predefined cutoff values at 60 ng/L for IL-6 and 0.25 ng/mL for PCT.
Results Seventy-seven FN episodes in 55 children with cancer were included. In 18 episodes (23.4%), a bacterial infection was
documented. Both at presentation and after 12–24 h, median values of IL-6 and PCTwere significantly higher in patients with a
bacterial infection compared to patients without a bacterial infection. With both biomarkers above cutoff values, sensitivity was
93% (with either one, this was even 100%). The identified group at low risk for bacterial infection comprised 41% of the
population.
Conclusion PCT and IL-6 are promising markers in identifying bacterial infection in children with cancer and FN. In a subse-
quent project, we will incorporate these biomarkers in a risk assessment model that we will test prospectively in a clinical trial.
Keywords Pediatric oncology . Febrile neutropenia . Bacterial infection . Biomarkers . Procalcitonin . Interleukin-6
Introduction
Children with cancer who develop fever after receiving che-
motherapy are usually immediately referred to the hospital. In
case their neutrophil count is very low, all patients used to be
hospitalized and treated with broad-spectrum intravenous an-
tibiotics until they become afebrile and neutrophil counts are
starting to recover [1]. This aggressive strategy to manage
febrile neutropenia has led to a great decrease in infection-
related mortality and morbidity [2, 3]. On the other hand,
studies have shown that only 20–30% of children with febrile
neutropenia have a proven bacterial infection [4, 5]. Other
causes of fever during chemotherapy may be the effect of
(chemotherapeutic) drugs, viral or fungal infections, blood
transfusions, mucositis, or the malignancy itself [4]. In recent
years, it has become practice to manage some patients with
low risk fever and neutropenia as an outpatient with oral an-
tibiotics. Being at low risk of systemic infection or sepsis,
these patients benefit from a milder approach, preventing
overtreatment [6, 7]. Yet, it is still very difficult to distinguish
children with and without bacterial infection upon presenta-
tion, because at that time, fever may be the only symptom of
bacterial infection [8]. Other symptoms are typically lacking,
since the diminished number of neutrophils causes an im-
paired inflammatory response [8, 9].
Various risk assessment strategies have previously been
proposed to rapidly determine whether a patient is at low or
high risk for bacterial infection at the moment of presentation
with febrile neutropenia. However, each risk assessment mod-
el has only been validated for its specific hospital setting,
region, and patient population. There is no international
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consensus or protocol with regard to the appropriate strategy
to use yet [1, 10].
Previously, we have shown that it is safe to withhold anti-
biotics in selected cancer patients who are at low risk of bac-
terial infection, based on a risk assessment model that includ-
ed objective clinical parameters in combination with the in-
fectious biomarker interleukin-8 (IL-8) [6]. In an additional
multicenter study, we have demonstrated that it is also safe to
shorten antibiotic treatment to 72 h in selected medium-risk
patients, based on the same clinical criteria and IL-8 [4].
IL-6 and PCT have been proposed by some investigators to
be just as good or even better than IL-8 at predicting bacterial
infection [11–14]. In addition, implementation of IL-6 and
PCT in the Netherlands might be more feasible, given the
pragmatic reason that in several Dutch hospitals IL-8 mea-
surement is seldomly performed and thus (1) not available
24-h a day and (2) is associated with high costs and long
waiting time.
In this study, we have evaluated the role of IL-6 and PCT,
separately and in combination, in diagnosing bacterial infec-
tion at the onset and 12–24 h after presentation with febrile
neutropenia.We were particularly curious to find out if we can
replace IL-8 by IL-6 and/or PCT in our original risk assess-
ment model and hence improve the model with regard to sen-
sitivity and specificity. With a better model, we might be able
to withhold antibiotics in more patients and discharge children
earlier, improving their quality of life.
Methods
Patients
This study was performed at the Department of Pediatric
Oncology and Hematology at the University Medical Center
of Groningen, the Netherlands. The study population was de-
rived from the database of the prospective IL-8 study by
Miedema et al. [4]. The inclusion criteria of this previous
study were maintained in this study; all outpatient pediatric
cancer patients that had presented with fever and
chemotherapy-induced neutropenia between June 2006 and
July 2013 were initially included. Body temperature was mea-
sured with a digital ear thermometer. Fever was invariably
defined as a single body temperature > 38.5 or two or more
recordings of > 38.0 during a period of 6 h. Neutropenia was
defined as absolute neutrophil count (ANC) < 0.5 × 109/L or,
if not available, leucocytes < 1.0 × 109/L. All patients had
undergone a physical examination. Additionally, routine
blood counts and diagnostic blood and other appropriate cul-
tures or diagnostic tests had been performed.
Plasma samples remaining after measurement of serum
levels of IL-8 had been stored for future research. In this study,
we determined plasma values of IL-6 and PCT on admission
(T0) and after 12–24 h (T1). Patients were excluded from this
study when no or not enough plasma was available to perform
laboratory tests for IL-6 and PCT at T0 and/or T1. Patients
who had received antibiotics other than the usual prophylactic
antibiotic treatment strategies or had undergone allogeneic
stem cell transplantation in the previous month had already
been excluded from the IL-8 study [4]. Medical records of all
the patients included in this study were reviewed to complete
missing data (e.g., x-thorax reports). Only the IL-8 values of
the patients included in this particular study were extracted
from the IL-8 database and included for proper comparison
with IL-6 and PCT values.
The institutional review board approved the IL-8 study
protocol. The study was registered at www.trialregister.nl,
trial ID number NTR3165. All patients and/or their parents,
dependent on age, have given informed consent for participa-
tion and storage of serum samples for future research [4].
Laboratory tests
Plasma samples had been stored at − 80 °C in EDTA tubes.
Plasma IL-6 values were measured in nanograms per liter
using an enzyme-linked immunosorbent assay (ELISA
Elecsys IL-6) assay. Plasma PCT levels were determined by
an enzyme-linked fluorescent immunoassay (VIDAS®
B.R.A.H.M.S. PCT™, provided by bioMérieux) and
displayed in nanograms per milliliter. The lower detection
limit was 0.05 ng/mL. Cutoff values were based on our pre-
vious research and literature findings and set at 60 ng/L and
0.25 ng/mL for IL-6 and PCT, respectively [6, 14, 15].
Group definitions
Patients were divided into two groups: with and without bac-
terial infection. Bacterial infection was defined as either micro-
biologically documented infection (a blood culture or culture
of fluid collected from an otherwise sterile site positive for a
bacterial pathogen) or radiologically documented infection
(pneumonia or sinusitis). In other words, the bacterial infection
group consists of patients that require antibiotics in any case.
Statistical analysis
Patient characteristics were summarized using descriptive sta-
tistics. Because data were not normally distributed, numerical
data were expressed as medians with ranges. Accordingly,
comparison between the two groups was performed using
the nonparametric Mann-Whitney U test. Categorical data
were compared using chi-square analysis. In all statistical
tests, two-sided p values of < 0.05 were considered signifi-
cant. All episodes, including repeated episodes in single pa-
tients, are treated as statistically independent. A sensitivity
analysis, including only a patient’s first episode of febrile
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neutropenia, was performed to validate the accuracy of this
decision rule. Receiver operating characteristics (ROC) curves
were constructed for each biomarker at each time point. The
area under the curve (AUC) was determined and cutoff values
for the biomarkers were determined and compared to the lit-
erature. Possible cutoff values from ROC analyses were based
on the Youden Index [15]. For the chosen cutoff values, the
predictive performances (sensitivity, specificity, positive pre-
dictive value, and negative predictive value) with correspond-
ing 95% confidence intervals (CIs) were calculated. CIs for
sensitivity and specificity are exact Clopper-Pearson CIs. CIs
for the predictive values are the standard logit CIs. Pearson
correlation coefficients were used to investigate potential re-
lationships between the biomarkers IL-8 and IL-6. Statistical
analysis was performed using SPSS for Mac OS X version 24
(SPSS, IBMCompany, Armonk, NewYork, USA). GraphPad
Prism for Mac OS X version 7.0 (GraphPad Software, La
Jolla, California, USA) was used to create graphics.
Results
Patient characteristics
One hundred sixty-five febrile neutropenic episodes were ini-
tially included in this study. Eighty-eight episodes were ex-
cluded, predominantly because no or not enough plasma sam-
ple was available for the determination of IL-6 and PCT. Thus,
a total of 77 episodes of febrile neutropenia in 55 childrenwith
cancer were included in this study. These patients presented
with febrile neutropenia between December 2008 and July
2013. Fifteen patients were enrolled more than once, with a
maximum of five times. In 18 of the 77 episodes (23.4%), a
bacterial infection was documented. Fourteen patients had
positive blood cultures and two patients had positive cultures
from another site (one patient with a perianal abscess and one
with multiple furuncles). In two patients, pneumonia was ra-
diographically confirmed.
To evaluate if the results from our selection of episodes
were representative for the entire IL-8 cohort, we compared
the characteristics of the excluded episodes (n = 88) and the
included episodes (n = 77). There were no significant differ-
ences between groups with respect to sex, age, diagnosis,
temperature, lab counts, and standard infection parameters.
The patient characteristics of the 77 included episodes and
55 children are shown in Table 1. With regard to sex, age, type
of cancer, temperature, and blood counts on admission (Hb,
leucocytes, neutrophils, and thrombocytes), no significant dif-
ferences were found between the group with and the group
without a bacterial infection. A difference in CRP levels on
admission was observed, but this was not significant (median
96 mg/L in the bacterial infection group vs. 36 mg/L in the
non-infectious group, p = 0.061). Serum values of IL-8 were
significantly higher in the group with bacterial infection than
in the group without bacterial infection, both on admission
(176 vs. 54 ng/L) and after 12–24 h (218 vs. 45 ng/L) with p
values of 0.002 and < 0.001, respectively.
Biomarkers
See Table 1 and Fig. 1. In 32 episodes, plasma samples were
available both at presentation (T0) and 12–24 h later (T1), in 32
episodes plasma samples at T0 only, and in 13 episodes at T1
only. IL-6 levels were significantly higher in patients with bac-
terial infection compared with patients without bacterial infec-
tion both at T0 and T1 (345.2 vs. 91.9 ng/L, p = 0.003 and 242
vs. 57 ng/L, p = 0.061). PCT levels were significantly elevated
in patients with bacterial infection compared with patients with-
out bacterial infection at T0 (1.00 vs. 0.32 ng/mL, p = 0.021)
and at T1 (1.80 vs. 0.38 ng/mL, p = 0.011), as well.
The discriminatory power of PCT and IL-6 markers for
bacterial infection in patients with febrile neutropenia was
evaluated using ROC curves, which are displayed in Fig. 2.
For bacterial infection, the AUC demonstrated good discrimi-
natory power for IL-6 on day 1 and day 2. On both time points,
PCT performed was not as good as IL-6, with fair discrimina-
tory power at T0 and poor discriminatory power at T1.
Table 2 shows the performance of IL-6 and PCT in terms of
sensitivity and specificity at T0 and T1, at cutoff values of
60 ng/L for IL-6 and 0.25 ng/ml for PCT. These cutoff values
were pre-chosen based on earlier research. The predefined
cutoff values were found to be accurate according to the
ROC analyses, based on the Youden Index and clinical rele-
vance. IL-6 showed 100% sensitivity at T0 and T1; for PCT,
this was 93.3 and 90% respectively. Values of IL-6 and IL-8
on both T0 and T1 correlated significantly (Pearson correla-
tion coefficient 0.776, p < 0.001 for admission and 0.958, p <
0.001 after 12–24 h).
The analyses were continued by constructing combinations
between IL-6 and PCT and evaluating their values in
distinguishing bacterial infections from other causes of fever.
Table 3 shows the p values, sensitivity, specificity, positive
predictive value (PPV), and negative predictive value (NPV)
of these combinations. With either one of the biomarkers
above the cutoff value, the sensitivity is 100%, both at T0
and T1. Thus, all patients with a bacterial infection were iden-
tified in this study population. However, the specificity was
low, identifying a low risk group of only 12 of 64 patients
(19%) on admission and 9 of 45 patients (20%) after 12–
24 h. Stating that both biomarkers had to be above the cutoff
value, more patients could be identified at low risk, namely 26
of 64 patients (41%) at T0 and 23 of 45 patients (51%) at T1.
However, one patient with a bacterial infection (a 13-year-old
boy with a perianal abscess) had a serum PCT level below the
cutoff value at both time points and consequently would have
been failed to notice using these criteria.
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Repeated episodes were treated as statistically independent
in all the aforementioned analyses. A sensitivity analysis (with
only the first episode per patient included) was performed to
validate this approach. This showed similar results with the
same statistical significance.
Discussion
In this study, we have investigated the diagnostic value of
various biomarkers for predicting bacterial infection in chil-
dren with cancer and febrile neutropenia. Our main aimwas to
identify patients that are at low risk for bacterial infection. We
found that both IL-6 and PCTare promising in doing so. Both
tests are highly sensitive, so the risk of missing a bacterial
infection is low. Further study of (a combination) of these
biomarkers might allow quick and safe identification of a
low risk group.
Traditionally, pediatric cancer patients who present with
febrile neutropenia are hospitalized and intravenous antibiotic
therapy is initiated immediately and continued for as long as
the neutropenia persists [1]. However, there is increasing ev-
idence that this aggressive management is excessive to apply
to all cases of febrile neutropenia (e.g., those with a viral
infection). [16, 17] A diagnostic test that can distinguish be-
tween the group of patients that can benefit from a milder
approach and patients at high risk for bacterial infection at
the time of presentation would thus be of great value.
Lehrnbecher et al. have emphasized this once more in the
recently updated Guideline for the Management of Fever and
Neutropenia in Children With Cancer [1]. Different research
groups in various countries have proposed risk models based
on a variety of biomarkers [2, 11–13, 16, 18–20] and clinical
observations [3, 21–23]. Due to heterogeneity of these studies,
it is currently not possible to extract a reliable, broadly appli-
cable decision rule. In a previously performed large, prospec-
tive study in the Netherlands, we have introduced a risk model
Table 1 Patient characteristics, clinical variables and laboratory parameters
All episodes Bacterial infection No bacterial infection p value
Number Patients 55 16 39
Episodes 77 (1, 1–5) 18 (1, 1–2) 59 (1, 1–5)
Sex–number (%) Male 34 (44.2%) 11 (61.1%) 23 (39%) 0.114a
Female 43 (55.8%) 7 (38.9%) 36 (61%)
Age (years) At diagnosis 5.7 (0.6–16.8) 3.8 (0.6–16.8) 6.1 (0.6–16.2) 0.177b
At inclusion 6.3 (0.8–18.8c) 5.0 (1.3–17.8) 80 (0.8–18.8c) 0.287b
Type of cancer Hematologic 44 (57.1%) 13 (72.2%) 31 (51.7%) 0.223a
Solid 26 (33.8%) 3 (16.7%) 23 (38.3%)
Brain 7 (9.1%) 2 (11.1%) 6 (10%)
Temperature (°C) 38.8 (34.2–40.2) 39.0 (38.0–40.2) 38.6 (34.2–40.1) 0.057b
Hemoglobin (mmol/L) 5.0 (2.5–7.3) 5.1 (2.5–7.3) 5.0 (3.0–6.7) 0.409b
Leukocytes ×109 0.40 (0.09–3.20) 0.3 (< 0.2–1.30) 0.50 (0.09–3.2) 0.142b
Neutrophils ×109 < 0.2 (< 0.2–0.50) < 0.2 (< 0.2–0.50) < 0.2 (< 0.2–0.42) 1.000b
Thrombocytes ×109 49 (1–820) 44 (1–404) 55 (1–820) 0.639b
CRP (mg/L) 47.5 (4–330) 96 (4–206) 36 (4–330) 0.061b
IL-8 (ng/L) T0d 79 (4–2214) 176 (30–1573) 54 (4–2214) 0.002b
T1e 61 (5–998) 218 (39–916) 45 (5–998) 0.000b
IL-6 (ng/L) T0 107 (3.9–2971) 345 (109–2971) 91.9 (3.9–1731) < 0.001b
T1 75 (8.4–10,380) 242 (66–10,380) 57 (8.4–705) 0.001b
PCT (ng/mL) T0 0.40 (0.05–15.74) 1.00 (0.17–15.74) 0.32 (0.05–15.39) 0.021b
T1 0.51 (0.04–48.0) 1.80 (0.12–48.0) 0.38 (0.04–5.49) 0.011b
Data are expressed as medians with ranges, unless specified otherwise. Temperature and blood samples for laboratory measurements were taken on
admission
CRP C-reactive protein, IL-6/IL-8 interleukin-6/-8, PCT procalcitonin, T0 time of presentation, T1 12 to 24 h after presentation
a Chi-square test
bMann-Whitney U test
c Only one patient of 18.8 years of age. All other patients were under 18 years of age
dAvailable in 76 episodes
e Available in 49 episodes
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based on objective clinical parameters and the biomarker IL-8
[4].With this model, we showed that it is feasible to distinguish
a low risk group (20%) of the patients presenting with febrile
neutropenia in clinical practice. We are planning a prospective
study in which we want to be able to distinguish a larger pro-
portion of patients with low risk of bacterial infection.
Therefore, as a first step, we have in this study analyzed the
discriminatory power of PCT and IL-6, since these two bio-
markers are suggested in multiple previous studies [2, 11–16,
18, 19, 24–29]. IL-6 is a cytokinewith important effects on the
development and differentiation of T and B lymphocytes and
hematopoietic cells. On admission, IL-6 has demonstrated to
be a sensitive marker for disease severity and it exhibits the
potential to be a better early discriminator than CRP for chil-
dren that will develop a serious infectious complication [2, 13,
19, 27–30]. PCTwas first suggested as a biomarker for infec-
tion almost 25 years ago [16, 25]. PCT is a prehormone of
calcitonin and serum levels of PCT increase in bacterial infec-
tion mainly due to the presence of bacterial endotoxins and
exotoxins and inflammatory cytokines. PCT has been shown
to reach plateau values within 8–24 h after the onset of a
bacterial infection [16, 19, 24].
A second motivation for this study was the problems we
encountered while introducing IL-8 in the clinical setting.
Fig. 1 Serum levels of IL-6 and
PCT. The central horizontal lines
mark themedians. PCT values are
plotted on a logarithmic scale
because of a wide spread in
values. Abbreviations used: IL-6,
interleukin-6; PCT, procalcitonin.
T0 = time of presentation, T1 = 12
to 24 h after presentation
A) ROC-curve at T0 B) ROC-curve at T1Fig. 2 ROC Curves for IL-6 and
PCT. a ROC curve at T0. b ROC
curve at T1. Abbreviations used:
ROC, receiver operator
characteristic; IL-6, interleukin-6;
PCT, procalcitonin. T0 = time of
presentation, T1 = 12 to 24 h after
presentation
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Measurements of IL-8 are currently not routinely performed in
our hospital laboratory, which makes it an expensive and im-
practical biomarker. In contrast, PCT and/or IL-6 measure-
ments are available at low cost and around the clock. Using
either or both of them would make the implementation of a
risk model, if proven feasible, easier, and more cost-effective.
In this study, IL-6 was shown to be a highly sensitive bio-
marker. At a cutoff level of 60 ng/L, both at presentation and at
12–24 h after presentation, it does not miss a single high risk
episode. In addition, L-6 values correlated well with IL-8
values, which supports the possibility of replacing IL-8 by
IL-6 in a risk model. PCTwas slightly less sensitive, missing
one episode of a 13-year-old boy with a perianal abscess. In
the clinical setting, biomarkers will always be used in addition
to clinical factors such as a detailed patient history and a phys-
ical examination. Translating this to the aforementioned epi-
sode categorized as low risk according to two subsequent PCT
measurements, this episode is unlikely to be regarded as low
risk in clinical practice. We expect any treating physician
would start antibiotic intravenous therapy regardless of labo-
ratory values in the case of a perianal abscess. In this study,
combining PCT and IL-6 led to the identification of an even
larger group of low risk episodes (on admission 41%, as com-
pared to 20% in the IL-8 study) [4].
When interpreting these findings, one should naturally take
the limitations of this study into account. First, although the
current study population and the majority of data were derived
from a prospective database (IL-8 study), additional data were
collected from medical records. This retrospective data is ex-
pected not to be as accurate or complete as prospectively col-
lected data. Second, another disadvantage of being a follow-
up study on a previous prospective trial is that not all plasma
samples originally taken were available anymore. Some pa-
tients had to be excluded completely; of other patients, only a
baseline or 12–24 h sample was available. This made it more
difficult to explore changes over time. Group sizes at T1 have
become small, which could be part of the reason for the non-
significant difference between the group with and without
bacterial infection while combining both biomarkers at this
time point (Table 3). Third, we did not investigate viral or
fungal infections. It would have been valuable to take other
identifiable origins of fever than bacterial infections into ac-
count. Fourth and final, we did not take vital signs or other
clinical criteria into account, as these were not retrievable from
Table 2 Predictive value of IL-6 and PCT
AUC Cutoff Sensitivity (95% CIa) Specificity (95% CIa) PPV (95% CIb) NPV (95% CIb)
IL-6 (in ng/L) T0 0.879 60 ng/L 100% (78.2–100) 34.7% (21.7–49.6) 31.9% (27.7–36.5) 100%
T1 0.857 60 ng/L 100% (69.2–100) 54.2% (36.7–71.2) 38.5% (30.3–47.3) 100%
PCT (in ng/mL) T0 0.698 0.25 ng/mL 93.3% (68.1–99.8) 42.8% (28.8–57.8) 33.3% (27.5–39.8) 95.5% (75.5–99.3)
T1 0.766 0.25 ng/mL 90% (55.5–99.8) 37.1% (21.5–55.1) 29% (22.8–36.2) 92.9% (65.9–98.9)
Sensitivity and specificity to distinguish bacterial infection from other causes of fever. AUCs are based on the ROC curves displayed in Fig. 2
AUC area under the curve, PPV positive predictive value, NPV negative predictive value, CI confidence interval, IL-6 interleukin-6, PCT procalcitonin,
T0 time of presentation, T1 12 to 24 h after presentation
a Exact Clopper-Pearson CI
b Standard logit CI
Table 3 Predictive value combining biomarkers
Bacterial infection p valuea Sens (95% CIb) Spec (95% CIb) PPV (95% CIc) NPV (95% CIc)
Yes No
IL6 > 60 and PCT > 0.25 T0 14/15 23/49 0.01 93.3% (68.1–99.8) 53.1% (38.3–67.5) 37.8% (30.5–45.8) 96.3% (79.4–99.4)
T1 9/10 12/35 0.002 90.0% (55.5–99.8) 65.7% (47.8–80.9) 42.9% (31.2–55.4) 95.8% (77.9–99.3)
IL6 > 60 or PCT > 0.25 T0 15/15 37/49 0.033 100% (78.2–100) 24.5% (13.3–38.9) 28.8% (25.7–32.3) 100%
T1 10/10 26/35 0.073 100% (69.2–100) 25.7% (12.5–43.3) 27.7% (24.0–31.9) 100%
Combinations of IL-6 and PCT and their predictive value are given at T0 (the time of presentation) and T1 (12 to 24 h after presentation). In the first
decision rule, both biomarkers are above the cutoff value. In the second decision rule, either one of the biomarkers is above the cutoff value
IL-6 interleukin-6, PCT procalcitonin, Sens sensitivity, Spec specificity, PPV positive predictive value, NPV negative predictive value, CI confidence
interval
a Chi-square test
b Exact Clopper-Pearson CI
c Standard logit CI
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most patient records. Asmentioned before, this can be of great
interest when developing a risk model that combines bio-
markers and clinical findings [10].
In conclusion, PCTand IL-6 might be good alternatives for
IL-8 and CRP in identifying low risk febrile neutropenic epi-
sodes in children with cancer, especially when these bio-
markers are combined. In the near future, we plan to elaborate
on this work. First, we will perform a prospective validation
study. Patients will receive standard care while clinical data
and biomarkers at different times (e.g., on admission, after
24 h and after 48 h) are obtained. If the combination of bio-
markers and clinical data is successful (i.e., no missed high
risk episodes and identification of a significant low risk
group), the next step would be a large, prospective, multina-
tional trial in which we will use the identified optimal combi-
nation in a risk stratification model. With this, we aim to
decrease unnecessary antibiotic use and hospital admission
in children with cancer and febrile neutropenia, which has
the potential to contribute greatly to the quality of life in these
patients and their families.
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